Legislation designed to lower drug prices by cracking down on innovator companies that block or delay development of generic or biosimilar products is finally heading to the Senate floor. But stakeholder efforts to make the legislation more innovator-friendly will continue.
The Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act passed the Judiciary Committee in a 16-5 vote on...






